Psychotropic Medication Advisory Committee

Warning!

It seems that JavaScript is not working in your browser. It could be because it is not supported, or that JavaScript is intentionally disabled. Some of the features on CT.gov will not function properly with out javascript enabled.

Settings Menu

Language
High Contrast
High Contrast Mode On or Off switch
Font Size
Disclaimer

This is a test alert from the Office of the Governor. This alert displays across all sites under Sitecore and appears at the top of the page.

Have a question concerning the Coronavirus and the Department of Children and Families? E-Mail us: DCF.COVID-19@ct.gov

Psychotropic Medication Advisory Committee (PMAC)

PMAC E-Mail: getmeds.dcf@ct.gov

The FDA Warns Against the Use of Many Genetic Tests with Unapproved Claims to Predict Patient Response to Specific Medications: FDA Safety Communication

2020 Minutes

February
January

2019 Minutes

December
November
October
September
May
April
March
February
January

Archived Meeting Minutes

Handouts:

Appendix II Psychotropic Medication Monitoring Protocols (March2020)
CYP Metabolism of Psychotropic Medications
DCF and PMAC Position Paper on Supplements (September 2019)
Drug Review and Decision History by Date (July 2015)
Drug Review and Decision History by Drug (July 2015)
Drug Lists:
Brand Name/Generic Name Drug List (June 2016)
Generic Name/Brand Name Drug List (June 2016)
Guidelines for Psychotropic Medication Use in Children and Adolescents

DCF and PMAC position paper on supplements edited 9619